» Articles » PMID: 23351549

Characterizing Biobank Organizations in the U.S.: Results from a National Survey

Overview
Journal Genome Med
Publisher Biomed Central
Specialty Genetics
Date 2013 Jan 29
PMID 23351549
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Effective translational biomedical research hinges on the operation of 'biobanks,' repositories that assemble, store, and manage collections of human specimens and related data. Some are established intentionally to address particular research needs; many, however, have arisen opportunistically, in a variety of settings and with a variety of expectations regarding their functions and longevity. Despite their rising prominence, little is known about how biobanks are organized and function beyond simple classification systems (government, academia, industry).

Methods: In 2012, we conducted the first national survey of biobanks in the U.S., collecting information on their origins, specimen collections, organizational structures, and market contexts and sustainability. From a list of 636 biobanks assembled through a multi-faceted search strategy, representatives from 456 U.S. biobanks were successfully recruited for a 30-minute online survey (72% response rate). Both closed and open-ended responses were analyzed using descriptive statistics.

Results: While nearly two-thirds of biobanks were established within the last decade, 17% have been in existence for over 20 years. Fifty-three percent listed research on a particular disease as the most important reason for establishment; 29% listed research generally. Other reasons included response to a grant or gift, and intent to centralize, integrate, or harmonize existing research structures. Biobank collections are extraordinarily diverse in number and types of specimens and in sources (often multiple) from which they are obtained, including from individuals, clinics or hospitals, public health programs, and research studies. Forty-four percent of biobanks store pediatric specimens, and 36% include postmortem specimens. Most biobanks are affiliated in one or multiple ways with other entities: 88% are part of at least one or more larger organizations (67% of these are academic, 23% hospitals, 13% research institutes). The majority of biobanks seem to fill a particular 'niche' within a larger organization or research area; a minority are concerned about competition for services, although many are worried about underutilization of specimens and long-term funding.

Conclusions: Effective utilization of biobank collections and effective policies to govern their use will require understanding of the immense diversity found in organizational features, including the very different history and primary goals that many biobanks have.

Citing Articles

How to communicate and what to disclose to participants in a recall-by-genotype research approach: a multistep empirical study.

Tschigg K, Consoli L, Bruggemann N, Hicks A, Staunton C, Mascalzoni D J Community Genet. 2024; 15(6):615-630.

PMID: 39325315 PMC: 11645387. DOI: 10.1007/s12687-024-00733-8.


Efficient Use of Biological Data in the Web 3.0 Era by Applying Nonfungible Token Technology.

Wang G, Chen C, Jiang Z, Li G, Wu C, Li S J Med Internet Res. 2024; 26:e46160.

PMID: 38805706 PMC: 11167317. DOI: 10.2196/46160.


Strategies for Implementing Machine Learning Algorithms in the Clinical Practice of Radiology.

Chae A, Yao M, Sagreiya H, Goldberg A, Chatterjee N, MacLean M Radiology. 2024; 310(1):e223170.

PMID: 38259208 PMC: 10831483. DOI: 10.1148/radiol.223170.


Paediatric biobanking for health: The ethical, legal, and societal landscape.

Casati S, Ellul B, Mayrhofer M, Lavitrano M, Caboux E, Kozlakidis Z Front Public Health. 2022; 10:917615.

PMID: 36238242 PMC: 9551217. DOI: 10.3389/fpubh.2022.917615.


Positive association between research competitiveness of Chinese academic hospitals and the scale of their biobanks: A national survey.

Zhang Y, Bian Z, Chen Y, Jiang E, Chen T, Wang C Clin Transl Sci. 2022; 15(12):2909-2917.

PMID: 36177952 PMC: 9747119. DOI: 10.1111/cts.13408.


References
1.
Knoppers B, Isasi R . Stem cell banking: between traceability and identifiability. Genome Med. 2010; 2(10):73. PMC: 2988448. DOI: 10.1186/gm194. View

2.
Clayton E, McGuire A . The legal risks of returning results of genomics research. Genet Med. 2012; 14(4):473-7. PMC: 3779603. DOI: 10.1038/gim.2012.10. View

3.
Malin B, Loukides G, Benitez K, Clayton E . Identifiability in biobanks: models, measures, and mitigation strategies. Hum Genet. 2011; 130(3):383-92. PMC: 3621020. DOI: 10.1007/s00439-011-1042-5. View

4.
Gibbons S . Regulating biobanks: a twelve-point typological tool. Med Law Rev. 2009; 17(3):313-46. DOI: 10.1093/medlaw/fwp016. View

5.
McCarty C, Garber A, Reeser J, Fost N . Study newsletters, community and ethics advisory boards, and focus group discussions provide ongoing feedback for a large biobank. Am J Med Genet A. 2011; 155A(4):737-41. PMC: 3092645. DOI: 10.1002/ajmg.a.33896. View